195 related articles for article (PubMed ID: 10428276)
1. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
2. Tolerance of T-independent xeno-antibody responses in the hamster-to-rat xenotransplantation model is species-restricted but not tissue-specific.
Chong AS; Ma LL; Yin D; Blinder L; Shen J; Williams JW
Xenotransplantation; 2000 Feb; 7(1):48-57. PubMed ID: 10809057
[TBL] [Abstract][Full Text] [Related]
3. Modification of humoral responses by the combination of leflunomide and cyclosporine in Lewis rats transplanted with hamster hearts.
Chong AS; Ma LL; Shen J; Blinder L; Yin DP; Williams JW
Transplantation; 1997 Dec; 64(12):1650-7. PubMed ID: 9422397
[TBL] [Abstract][Full Text] [Related]
4. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide prolongs pulmonary allograft and xenograft survival.
Yuh DD; Gandy KL; Morris RE; Hoyt G; Gutierrez J; Reitz BA; Robbins RC
J Heart Lung Transplant; 1995; 14(6 Pt 1):1136-44. PubMed ID: 8719461
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide controls rejection in hamster to rat cardiac xenografts.
Xiao F; Chong AS; Foster P; Sankary H; McChesney L; Koukoulis G; Yang J; Frieders D; Williams JW
Transplantation; 1994 Oct; 58(7):828-34. PubMed ID: 7940718
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
10. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
12. Histological and immunological characteristics of, and the effect of immunosuppressive treatment on, xenograft vasculopathy.
Briffa NP; Shorthouse R; Chan J; Silva H; Billingham M; Brazelton T; Morris RE
Xenotransplantation; 2004 Mar; 11(2):149-59. PubMed ID: 14962277
[TBL] [Abstract][Full Text] [Related]
13. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
14. Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation.
Shen J; Chong AS; Xiao F; Liu W; Huang W; Blinder L; Foster P; Sankary H; Jensik S; McChesney L; Mital D; Williams JW
Transplantation; 1998 Sep; 66(6):692-8. PubMed ID: 9771831
[TBL] [Abstract][Full Text] [Related]
15. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
16. Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
Silva HT; Shorthouse R; Morris RE
Transplant Proc; 1996 Dec; 28(6):3092-4. PubMed ID: 8962197
[No Abstract] [Full Text] [Related]
17. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation.
Sankary HN; Yin DP; Chong AS; Ma LL; Blinder L; Shen JK; Foster P; Williams JW
Transplantation; 1998 Oct; 66(7):832-7. PubMed ID: 9798690
[TBL] [Abstract][Full Text] [Related]
18. Induction of species-specific host accommodation in the hamster-to-rat xenotransplantation model.
Yin D; Ma LL; Blinder L; Shen J; Sankary H; Williams JW; Chong AS
J Immunol; 1998 Aug; 161(4):2044-51. PubMed ID: 9712078
[TBL] [Abstract][Full Text] [Related]
19. Blood distribution and single-dose pharmacokinetics of leflunomide.
Lucien J; Dias VC; LeGatt DF; Yatscoff RW
Ther Drug Monit; 1995 Oct; 17(5):454-9. PubMed ID: 8585107
[TBL] [Abstract][Full Text] [Related]
20. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
Chong AS; Zeng H; Knight DA; Shen J; Meister GT; Williams JW; Waldman WJ
Am J Transplant; 2006 Jan; 6(1):69-75. PubMed ID: 16433758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
